Advanced Management of the Dermatologic Manifestations of Scleroderma

The presentation focused on the advanced management of dermatologic manifestations of scleroderma, highlighting distinguishing clinical features and management challenges through illustrative case studies. The first case discussed involved a patient with generalized morphia, signaling the importance of differentiating between morphia and systemic sclerosis, as they share similar histologic findings yet have different prognoses. The speaker emphasized that morphia does not progress to systemic sclerosis, providing reassurance to patients. The discussion transitioned to systemic sclerosis in a second case of a woman with severe cutaneous sclerosis reflecting the rapid onset of symptoms indicative of this condition. The lecture addressed diagnostic criteria, emphasizing the significance of skin thickening, nail fold capillary changes, and specific auto-antibodies linked to different disease phenotypes. Treatment options explored included mycophenolate mofetil and emerging therapies like rituximab and JAK inhibitors, alongside the role of corticosteroids. The importance of managing pruritus and the healing of skin ulcers was also discussed, underlining the complexity of patient care and potential multifactorial causes of ulcers in scleroderma patients. Additional cases illustrated long-standing complications, including calcinosis and its challenging management options, expressing the impact of these conditions on quality of life. Lastly, a contrasting case of eosinophilic fasciitis was presented, demonstrating the necessity of precise diagnosis in skin tightening conditions post-COVID. Overall, the speaker highlighted the nuanced approach required in treating scleroderma and related conditions, sharing insights on current treatments and ongoing research.